Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1971 1
1979 1
1984 4
1985 11
1986 8
1987 86
1988 144
1989 309
1990 352
1991 364
1992 389
1993 449
1994 494
1995 496
1996 510
1997 469
1998 608
1999 628
2000 670
2001 601
2002 573
2003 658
2004 802
2005 924
2006 1195
2007 1442
2008 1613
2009 2010
2010 2344
2011 2796
2012 2858
2013 3100
2014 3394
2015 3504
2016 3766
2017 3749
2018 3723
2019 2078
2020 23
Text availability
Article attribute
Article type
Publication date

Search Results

41,381 results
Results by year
Filters applied: . Clear all
Page 1
Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy.
Yong T, et al. Nat Commun 2019. PMID 31444335 Free PMC article.
Here, we develop a biocompatible tumor-cell-exocytosed exosome-biomimetic porous silicon nanoparticles (PSiNPs) as drug carrier for targeted cancer chemotherapy. ...These results provide a proof-of-concept for the use of exosome-biomimetic nanoparticles exocytosed from tumor cells as a promising drug carrier for efficient cancer chemotherapy....
Here, we develop a biocompatible tumor-cell-exocytosed exosome-biomimetic porous silicon nanoparticles (PSiNPs) as drug carrier for t …
Targeted acetylcholinesterase-responsive drug carriers with long duration of drug action and reduced hepatotoxicity.
Lin Y, et al. Int J Nanomedicine 2019. PMID 31440049 Free PMC article.
Comparison of AChE activity between drug-loading system and inhibitor was developed with kits and by ELISA method. The efficacy of drug-loaded nanocarriers was investigated in a mouse model. ...Critically, the drug delivery system can not only exhibit long duration of drug action on AChE inhibition but also reduce the hepatotoxicity in vivo. ...
Comparison of AChE activity between drug-loading system and inhibitor was developed with kits and by ELISA method. The efficacy of …
Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide.
Wu LP, et al. Nat Commun 2019. PMID 31604928 Free PMC article.
Here we show hierarchial forms of a brain-specific phage-derived peptide (herein as NanoLigand Carriers, NLCs) target cerebral endothelial cells through transferrin receptor and the receptor for advanced glycation-end products, cross the blood-brain-barrier and reach neurons and microglial cells. ...
Here we show hierarchial forms of a brain-specific phage-derived peptide (herein as NanoLigand Carriers, NLCs) target cerebral endoth …
Design of colloidal drug carriers of celecoxib for use in treatment of breast cancer and leukemia.
Üner M, et al. Mater Sci Eng C Mater Biol Appl 2019. PMID 31349508
Nanoscale drug carriers are required to be investigated for delivery of actives at cellular level for treatment of various cancer types. Solid lipid nanoparticles (CLX-SLN), nanostructured lipid carriers (CLX-NLC) and a nanoemulsion (CLX-NE) of celecoxib (CLX), a selective cyclooxygenase-2 inhibitor, were formulated for use in remedy of breast cancer and acute promyelocytic leukemia. ...
Nanoscale drug carriers are required to be investigated for delivery of actives at cellular level for treatment of various can …
Maleimide-functionalised PLGA-PEG nanoparticles as mucoadhesive carriers for intravesical drug delivery.
Kaldybekov DB, et al. Eur J Pharm Biopharm 2019. PMID 31419584
Low permeability of the urinary bladder epithelium, poor retention of the chemotherapeutic agents due to dilution and periodic urine voiding as well as intermittent catheterisations are the major limitations of intravesical drug delivery used in the treatment of bladder cancer. ...PLGA-PEG-Mal nanoparticles were explored as mucoadhesive formulations for drug delivery to the urinary bladder. The retention of fluorescein-loaded nanoparticles on freshly excised lamb bladder mucosa in vitro was evaluated and assessed using a flow-through fluorescence technique and Wash Out(50) (WO(50)) quantitative method. ...
Low permeability of the urinary bladder epithelium, poor retention of the chemotherapeutic agents due to dilution and periodic urine voiding …
Drug micro-carriers with a hyaluronic acid corona toward a diffusion-limited aggregation within the vitreous body.
Mayol L, et al. Carbohydr Polym 2019. PMID 31196539
Moreover, a rational design of these MPs requires a discouraged diffusion/sedimentation within the intravitreal space, which are detrimental for the vision and the control over drug release kinetics. ...
Moreover, a rational design of these MPs requires a discouraged diffusion/sedimentation within the intravitreal space, which are detrimental …
Design and preparation of mesoporous silica carriers with chiral structures for drug release differentiation.
Wang Y, et al. Mater Sci Eng C Mater Biol Appl 2019. PMID 31349514
The crystalline state of IBU was effectively converted to amorphous state after being incorporated into CMSs, and the drug delivery systems shared the chiral characteristic of carriers. ...Particularly, due to the different pore geometry of these two materials, CMSs with different chirality (D/L) could be applied as carriers to accomplish drug release differentiation....
The crystalline state of IBU was effectively converted to amorphous state after being incorporated into CMSs, and the drug delivery s …
Platelets and their biomimetics for regenerative medicine and cancer therapies
Li Z, et al. J Mater Chem B 2018 - Review. PMID 31372220 Free PMC article.
Among these are their enhanced circulation time, their large volumes and surface areas for drug loading or conjugation, and their inherent ability to target some diseases. ...
Among these are their enhanced circulation time, their large volumes and surface areas for drug loading or conjugation, and their inh …
41,381 results
Jump to page
Feedback